$MRNA stock has now fallen 5% today, according to our price data from Polygon. There has been approximately $51,043,823 of trading volume.
It has been the 33rd most-searched ticker on Quiver Quantitative over the last day, out of 11,840 total tickers searched.
Here is what we see in our data on $MRNA (you can track the company live on Quiver's $MRNA stock page):
$MRNA Insider Trading Activity
$MRNA insiders have traded $MRNA stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) sold 160,009 shares for an estimated $7,814,839
- NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
- ABBAS HUSSAIN sold 504 shares for an estimated $13,910
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MRNA Hedge Fund Activity
We have seen 259 institutional investors add shares of $MRNA stock to their portfolio, and 395 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 15,741,014 shares (+127.9%) to their portfolio in Q4 2025, for an estimated $464,202,502
- CAPITAL WORLD INVESTORS added 12,828,040 shares (+inf%) to their portfolio in Q4 2025, for an estimated $378,298,899
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,254,709 shares (-79.7%) from their portfolio in Q4 2025, for an estimated $184,451,368
- ALYESKA INVESTMENT GROUP, L.P. added 3,228,531 shares (+inf%) to their portfolio in Q4 2025, for an estimated $95,209,379
- BNP PARIBAS FINANCIAL MARKETS added 3,058,933 shares (+279.7%) to their portfolio in Q4 2025, for an estimated $90,207,934
- BLACKROCK, INC. added 2,977,816 shares (+10.1%) to their portfolio in Q4 2025, for an estimated $87,815,793
- CITADEL ADVISORS LLC removed 1,408,601 shares (-70.9%) from their portfolio in Q4 2025, for an estimated $41,539,643
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MRNA Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 3 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
- Leerink Partners issued a "Underperform" rating on 11/21/2025
- B of A Securities issued a "Underperform" rating on 11/10/2025
- UBS issued a "Buy" rating on 10/23/2025
- JP Morgan issued a "Underweight" rating on 10/23/2025
To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.
$MRNA Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 12 analysts offer price targets for $MRNA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $69.0 on 02/23/2026
- Luca Issi from RBC Capital set a target price of $30.0 on 02/17/2026
- Cory Kasimov from Evercore ISI Group set a target price of $35.0 on 02/17/2026
- Salveen Richter from Goldman Sachs set a target price of $41.0 on 02/17/2026
- Eliana Merle from UBS set a target price of $34.0 on 01/07/2026
- Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025
- Matthew Harrison from Morgan Stanley set a target price of $28.0 on 12/12/2025
You can track data on $MRNA on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
